Nashville Biosciences
Private Company
Funding information not available
Overview
Founded in 2019, Nashville Biosciences is a private data-enabling platform company that commercializes access to one of the world's largest and richest linked biorepositories, BioVU®, from Vanderbilt University Medical Center. The company transforms complex, real-world healthcare data—including electronic health records, genomic sequences, biosamples, and medical imaging—into structured, research-ready datasets for pharmaceutical, diagnostic, and AI developers. By providing enriched, demographically diverse, and longitudinally deep data, NashBio aims to de-risk and accelerate the R&D pipeline for its partners, which include many top-tier biopharma companies. It operates on a B2B services and data licensing model, generating revenue by providing data access and advanced analytical services.
Technology Platform
A multimodal data platform centered on Vanderbilt University Medical Center's BioVU® biobank, providing linked and de-identified electronic health records, genomic data (whole-exome sequencing, genotyping), biosamples, medical imaging, and waveform data, curated for research and discovery.
Opportunities
Risk Factors
Competitive Landscape
NashBio competes in the real-world data (RWD) and real-world evidence (RWE) market against large CROs and data giants like IQVIA and Flatiron Health (Ontada), as well as other genomics-focused players like Regeneron Genetics Center and Tempus. Its primary differentiation is the unparalleled depth of linkage between longitudinal clinical records, diverse biosamples, and extensive genomic data from a single, prestigious academic medical center, offering quality over sheer volume.